Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
1. 系统已在2026-07-01 16:21:41对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/JCO-25-01969
文献链接: https://ascopubs.org/doi/10.1200/JCO-25-01969
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Wenqiang Yan; Chenxing Du; Rui Lv; Hesong Zou; Shuaishuai Zhang; Tengteng Yu; Yuting Yan; Yanlei Zhang; Shuixiu Peng; Tingyu Wang; Shuhui Deng; Wenyang Huang; Shuhua Yi; Dehui Zou; Tao Cheng; Jianxiang Wang; Alex H. Chang; Lugui Qiu; Gang An

